Upon viewing this session, you will be able to:
• Review the data from clinical trials that have evaluated the feasibility of discontinuation of TKI therapy in patients with chronic phase CML.
• Identify the criteria required to attempt discontinuation of TKI therapy, and the prognostic factors associated with recurrence after stopping TKI therapy.
Neil Shah, MD, PhD, University of Califronia – San Francisco
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members